ModifiedUnitedHealthcarePolicy CSPA2025D0095H

Viltepso (Viltolarsen) (for Pennsylvania Only)

This medical benefit drug policy governs coverage and authorization requirements for Viltepso (viltolarsen) for the treatment of Duchenne muscular dystrophy in Pennsylvania members, including initial and continuation therapy criteria and applicable billing codes.

Policy Summary

PayerUnitedHealthcare

PolicyViltepso (Viltolarsen) (for Pennsylvania Only)

Policy CodePolicy CSPA2025D0095H

Change TypeRevised coverage criteria (prior gene therapy requirement added)

Effective DateAug 1, 2025

Next Review DateN/A

Key ActionSubmit medical records documenting DMD diagnosis amenable to exon 53 skipping and, if prior gene therapy was given, documentation of clinically meaningful functional decline.

SourceLink

POLICY UPDATE CHANGES

Revised coverage criteria for initial therapy to require one of the following: patient has not previously received gene therapy for DMD, or patient previously received gene therapy and has documented clinically meaningful functional decline since gene therapy.

Revised coverage criteria for initial therapy to add a requirement that the patient either has not previously received gene therapy for DMD or, if previously treated with gene therapy, must have documentation of a clinically meaningful functional decline since that therapy.

Archived previous policy version CSPA2025D0095G was noted in supporting information.

up to 12 moauthorization period

J1427HCPCS

G71.01

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

1prior gene therapy req

Coverage and Medical Necessity Criteria

Initial Therapy

Viltepso may be covered when ALL of the following are met:

Initial Therapy: Diagnosis of Duchenne muscular dystrophy by, or in consultation with, a neurologist with expertise in the diagnosis of DMD

Genetic confirmation: Submission of medical records (e.g., chart notes, laboratory values) confirming the mutation of the DMD gene is amenable to exon 53 skipping

Baseline assessment: Submission of medical records documenting a baseline evaluation, including a standardized assessment of motor function by a neurologist with experience in treating Duchenne muscular dystrophy, prior to beginning Viltepso therapy

Prior gene therapy status: One of the following: Patient has not previously received gene therapy (e.g., Elevidys) for the treatment of DMD; OR Patient previously received gene therapy for the treatment of DMD and submission of medical records documenting a clinically meaningful functional decline resulting from loss of muscle strength/motor ability (e.g., loss of a motor milestone) since receiving gene replacement therapy

Both options acceptable; documentation of decline required if prior gene therapy was given.

Concomitant therapy restriction: Viltepso is not used concomitantly with other exon skipping therapies for DMD (e.g., Amondys, Exondys 51, Vyondys 53)

Prescriber requirement: Prescribed by, or in consultation with, a neurologist with expertise in the treatment of DMD

Dosing requirement: Dosing is in accordance with the United States Food and Drug Administration approved labeling

Authorization duration: Initial authorization will be for no more than 12 months

Initial therapy — prior gene therapy requirement

Revised coverage criteria for initial therapy now require in addition that either:

Prior gene therapy requirement: Either the patient has not previously received gene therapy (e.g., Elevidys) for the treatment of DMD; OR both of the following are met: (1) patient previously received gene therapy for DMD, and (2) submission of medical records (e.g., chart notes, laboratory values) documenting a clinically meaningful functional decline resulting from loss of muscle strength/motor ability (e.g., loss of a motor milestone) since receiving gene replacement therapy

This pathway permits coverage after prior gene therapy only when documentation of clinically meaningful decline is provided.

Continuation Therapy

Reauthorization may be granted when ALL of the following are met:

Clinical benefit: Documentation of continued clinical benefit based on prescriber's assessment, including an evaluation with a standardized assessment of motor function ability by a neurologist with experience in treating Duchenne muscular dystrophy

Concomitant therapy restriction: Viltepso is not used concomitantly with other exon skipping therapies for DMD (e.g., Amondys, Exondys 51, Vyondys 53)

Prescriber requirement: Prescribed by, or in consultation with, a neurologist with expertise in the treatment of DMD

Dosing requirement: Dosing is in accordance with the United States Food and Drug Administration approved labeling

Unproven/Not Medically Necessary

Unproven indications: Viltepso is unproven and not medically necessary for the treatment of other forms of muscular dystrophy (e.g., Becker muscular dystrophy)

Requests outside the stated criteria will be reviewed for medical necessity on a case-by-case basis.

Use of Viltepso (viltolarsen) for indications outside Duchenne muscular dystrophy that is amenable to exon 53 skipping is considered unproven and not medically necessary. Examples include Becker muscular dystrophy. Requests for such uses will be reviewed case‑by‑case for medical necessity.

Treatment of muscular dystrophies other than DMD that are not clearly amenable to exon 53 skipping (for example, Becker muscular dystrophy) is not medically necessary.

Some sections of the policy history and revision notes do not contain explicit not medically necessary statements. Where explicit exclusion language is absent in archived or revision excerpts, clinical determination should default to the policy’s stated coverage criteria and the documented intent of the revision (see policy history for details).

Billing and Diagnosis Codes

HCPCS CodesHCPCS

J1427

Injection, viltolarsen, 10 mg

Diagnosis CodesICD-10

G71.01

Duchenne or Becker muscular dystrophy

Prior Authorization, Documentation, and Provider Requirements

Prior Authorization

Prior Authorization Required

Prior Authorization Required: Prior authorization is required for Viltepso (viltolarsen). Authorization must document that the patient meets initial therapy criteria, including neurologist involvement, genetic confirmation of a DMD mutation amenable to exon 53 skipping, and a baseline standardized motor function assessment performed by a neurologist experienced in DMD.

Prescribed by, or in consultation with, a neurologist with expertise in the diagnosis/treatment of DMD
Submission of medical records confirming DMD mutation amenable to exon 53 skipping (e.g., genetic test report)
Submission of baseline evaluation including a standardized motor function assessment by a neurologist prior to initiating therapy
Initial authorization limited to no more than 12 months

Prior Authorization

Prior Gene Therapy Status — Documentation Required

Prior gene therapy status must be clearly documented. The record must indicate whether the patient has never received gene replacement therapy for DMD (e.g., Elevidys) or, if previously treated, must include documentation of clinically meaningful functional decline since receiving gene therapy.

Key Definitions

Amenable to exon 53 skipping — definition

DefinitionA confirmed mutation of the DMD gene (typically an out-of-frame deletion) that can be targeted by viltolarsen to skip exon 53, allowing production of an internally truncated dystrophin protein.

Population prevalenceApproximately 8%–10% of DMD patients have mutations amenable to exon 53 skipping.

MechanismAmenable mutations permit antisense oligonucleotide–mediated exclusion of exon 53 from dystrophin pre-mRNA, which may restore the reading frame and increase dystrophin production.

Clinical requirementGenetic confirmation (documentation that the DMD gene mutation is amenable to exon 53 skipping) is required for coverage consideration.

viltolarsen (Viltepso) — drug identity

Generic and brand name

Clinical Background

Duchenne muscular dystrophy (DMD) is an X‑linked disorder characterized by progressive muscle weakness due to absence of functional dystrophin from loss‑of‑function variants in the DMD gene. Viltolarsen is an antisense oligonucleotide designed to induce exon 53 skipping to produce an internally truncated dystrophin protein for patients with mutations amenable to exon 53 skipping (approximately 8–10% of DMD patients).

Policy Revision History

2025-08-01policy_revisionLatest

Revised coverage criteria for initial therapy to add a requirement addressing prior gene replacement therapy: either the patient has not previously received gene therapy (e.g., Elevidys) for DMD, or if previously treated with gene therapy, submission of medical records documenting a clinically meaningful functional decline since gene therapy is required.

Policy Summary

PayerUnitedHealthcare

PolicyViltepso (Viltolarsen) (for Pennsylvania Only)

Policy CodePolicy CSPA2025D0095H

Change TypeRevised coverage criteria (prior gene therapy requirement added)

Effective DateAug 1, 2025

Next Review DateN/A

Key ActionSubmit medical records documenting DMD diagnosis amenable to exon 53 skipping and, if prior gene therapy was given, documentation of clinically meaningful functional decline.

SourceLink

On This Page

Authorization duration: Reauthorization will be for no more than 12 months

If no prior gene therapy: documentation stating the patient has not received prior gene therapy for DMD
If prior gene therapy: medical records (chart notes, standardized assessments, laboratory values) documenting clinically meaningful functional decline (e.g., loss of motor milestone, loss of muscle strength/motor ability) since gene therapy

Documentation Required

Concomitant Therapy Restriction

Concomitant exon skipping therapy restriction: Viltepso must not be used at the same time as other exon skipping therapies for DMD.

Examples of prohibited concomitant exon skipping therapies: Amondys (casimersen), Exondys 51 (eteplirsen), Vyondys 53 (golodirsen)

Documentation Required

Required Documentation — Baseline and Confirmation

Required Documentation for Prior Authorization: Provide complete supporting records to avoid delays or denial.

Genetic test report confirming a DMD mutation amenable to exon 53 skipping
Baseline standardized motor function assessment performed and documented by a neurologist experienced in DMD (chart notes and assessment scores)
Prescriber documentation that Viltepso is prescribed by, or in consultation with, a neurologist with DMD expertise
Dosing plan consistent with FDA-approved labeling
If previously treated with gene therapy, see additional documentation requirements below

Denial Risk

Documentation Related to Prior Gene Therapy — Risk of Denial if Missing

Documentation When Prior Gene Therapy: If the member has previously received gene replacement therapy for DMD, submit medical records demonstrating clinically meaningful functional decline after that therapy; failure to document prior gene therapy status or decline may result in denial.

Documentation must include dates and type of prior gene therapy (e.g., Elevidys) and objective clinical evidence of decline (e.g., loss of a motor milestone, decline on standardized motor function tests) since treatment
Chart notes, standardized motor assessments, and other relevant medical records that establish timing and extent of decline

Denial Risk

Triggers for Potential Denial

Triggers for Potential Denial: Common reasons authorizations may be denied if documentation is incomplete or criteria are unmet.

Missing documentation of a DMD mutation amenable to exon 53 skipping
No documentation that a neurologist with DMD expertise diagnosed or consulted on the case
Absence of a baseline standardized motor function assessment prior to starting therapy
Failure to document prior gene therapy status (treated vs not treated) or, if treated, failure to provide records showing clinically meaningful functional decline after gene therapy
Requests that propose concomitant use with other exon skipping therapies

Viltolarsen (brand: Viltepso).

Drug classAntisense oligonucleotide designed to bind exon 53 of dystrophin pre-mRNA and induce exon 53 skipping.

FDA indicationIndicated for treatment of Duchenne muscular dystrophy in patients with a confirmed DMD gene mutation amenable to exon 53 skipping (accelerated approval).

Key evidence sourcesViltepso package insert and clinical trials (see references including JAMA Neurol and J Neuromuscul Dis listings).

Gene therapy example — Elevidys (delandistrogene moxparvovec-rokl)

Example gene replacement therapyElevidys (delandistrogene moxparvovec-rokl).

Policy relevancePrior receipt of gene therapy (e.g., Elevidys) is an explicit consideration in initial coverage criteria; either no prior gene therapy or documentation of clinically meaningful functional decline since gene therapy is required.

Documentation required if prior treatedIf previously received gene replacement therapy, submit medical records documenting clinically meaningful functional decline (e.g., loss of a motor milestone) since the gene therapy.